S
Sling Therapeutics
Late-stage oral IGF-1R therapy for thyroid eye disease
About Sling Therapeutics
Sling Therapeutics is an Ann Arbor clinical-stage biopharmaceutical company developing linsitinib, an oral small-molecule IGF-1R inhibitor for thyroid eye disease (TED), aiming to offer a convenient alternative to lengthy IV/injectable IGF-1R regimens and orbital surgery. Led by President and CEO Ryan Zeidan, Ph.D., Sling completed the Phase 2b/3 LIDS trial that met its primary endpoint of proptosis reduction with a differentiated safety profile in areas such as hearing, glycemic and menstrual effects, earned U.S. FDA Fast Track designation, and has commenced the global Phase 3 ORBIT pivotal trial in moderate-to-severe active TED after End-of-Phase 2 alignment with FDA. In September 2026 Sling closed a $123 million Series C led by Forbion, with existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management, appointing Forbion’s Regina Salvat and Sectoral’s François Beaubien to the board; proceeds fund continued Phase 3 advancement of linsitinib toward commercialization. Sources: Sling Therapeutics 16 Sep 2026; Forbion / BioSpace 16 Sep 2026.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Ann Arbor, United States
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 39.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Ophthalmology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2022 | $35M | $140M | The Rise Fund (TPG) | ↗ |
Growth signals
Latest recorded traffic for Sling Therapeutics is 1.2K monthly website visits, down 14.3% over the last three months. Sling Therapeutics's team declined 7.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
The Rise Fund (TPG)
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sling Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sling Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.